These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 17954189

  • 21. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [Abstract] [Full Text] [Related]

  • 22. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.
    Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, Piscaglia F, Tamè M, Pinna AD.
    Liver Transpl; 2009 Jul; 15(7):782-9. PubMed ID: 19562715
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study.
    Marin-Gomez LM, Gomez-Bravo MA, Alamo-Martinez JA, Barrera-Pulido L, Bernal Bellido C, Suárez Artacho G, Pascasio JM.
    Transplant Proc; 2009 Jul; 41(6):2184-6. PubMed ID: 19715867
    [Abstract] [Full Text] [Related]

  • 24. Amantadine therapy in renal transplant patients with hepatitis C virus infection.
    Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J.
    J Clin Virol; 2004 May; 30(1):110-4. PubMed ID: 15072764
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
    Burra P, Senzolo M, Masier A, Prestele H, Jones R, Samuel D, Villamil F.
    Dig Liver Dis; 2009 May; 41(5):350-6. PubMed ID: 19046932
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient.
    Pollard S.
    Liver Int; 2004 Oct; 24(5):402-6. PubMed ID: 15482334
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus.
    Zawiasa A, Szklarek-Kubicka M, Fijałkowska-Morawska J, Nowak D, Rysz J, Mamełka B, Nowicki M.
    Transplant Proc; 2009 Oct; 41(1):188-91. PubMed ID: 19249511
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Spontaneous clearance of HCV in HIV-hepatitis C virus coinfected liver transplant patients: prospective study.
    Gutiérrez-Moreno M, Bernal-Bellido C, Suárez-Artacho G, Alamo-Martínez JM, Marín-Gómez LM, Serrano-Díaz-Canedo J, Padillo-Ruiz FJ, Gómez-Bravo MA.
    Transplant Proc; 2012 Sep; 44(7):2100-2. PubMed ID: 22974923
    [Abstract] [Full Text] [Related]

  • 34. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 35. Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease.
    Inoue K, Yoshiba M.
    Transplant Proc; 2005 Mar 15; 37(2):1233-4. PubMed ID: 15848679
    [Abstract] [Full Text] [Related]

  • 36. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.
    Yu X, Zhang B, Xing C, Sun B, Liu M, Zhang W, Gu M.
    Transplant Proc; 2008 Dec 15; 40(10):3455-9. PubMed ID: 19100412
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis.
    Samonakis DN, Cholongitas E, Triantos CK, Griffiths P, Dhillon AP, Thalheimer U, Patch DW, Burroughs AK.
    J Hepatol; 2005 Dec 15; 43(6):1091-3. PubMed ID: 16239045
    [Abstract] [Full Text] [Related]

  • 39. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.
    Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, Cabrera R, Reed AI, Liu C, Nelson DR.
    Liver Transpl; 2006 Jan 15; 12(1):51-7. PubMed ID: 16382464
    [Abstract] [Full Text] [Related]

  • 40. The use of hepatitis C viral RNA levels in liver tissue to distinguish rejection from recurrent hepatitis C.
    Gottschlich MJ, Aardema KL, Burd EM, Nakhleh RE, Brown KA, Abouljoud MS, Hirst K, Moonka DK.
    Liver Transpl; 2001 May 15; 7(5):436-41. PubMed ID: 11349265
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.